Melanie P Chin1, George L Bakris2, Geoffrey A Block3, Glenn M Chertow4, Angie Goldsberry1, Lesley A Inker5, Hiddo J L Heerspink6, Megan O'Grady1, Pablo E Pergola7, Christoph Wanner8, David G Warnock9, Colin J Meyer1. 1. Reata Pharmaceuticals, Irving, Texas, USA. 2. University of Chicago Medicine, Chicago, Illinois, USA. 3. Denver Nephrology, Denver, Colorado, USA. 4. Stanford University School of Medicine, Stanford, California, USA. 5. Tufts Medical Center, Boston, Massachusetts, USA. 6. Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 7. Renal Associates, San Antonio, Texas, USA. 8. University of Wurzburg, Wurzburg, Germany. 9. University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
BACKGROUND: Increases in measured inulin clearance, measured creatinine clearance, and estimated glomerular filtration rate (eGFR) have been observed with bardoxolone methyl in 7 studies enrolling approximately 2,600 patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The largest of these studies was Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), a multinational, randomized, double-blind, placebo-controlled phase 3 trial which enrolled patients with T2D and CKD stage 4. The BEACON trial was terminated after preliminary analyses showed that patients randomized to bardoxolone methyl experienced significantly higher rates of heart failure events. We performed post-hoc analyses to characterize changes in kidney function induced by bardoxolone methyl. METHODS: Patients in -BEACON (n = 2,185) were randomized 1: 1 to receive once-daily bardoxolone methyl (20 mg) or placebo. We compared the effects of bardoxolone methyl and placebo on a post-hoc composite renal endpoint consisting of ≥30% decline from baseline in eGFR, eGFR <15 mL/min/1.73 m2, and end-stage renal disease (ESRD) events (provision of dialysis or kidney transplantation). RESULTS: Consistent with prior studies, patients randomized to bardoxolone methyl experienced mean increases in eGFR that were sustained through study week 48. Moreover, increases in eGFR from baseline were sustained 4 weeks after cessation of treatment. Patients randomized to bardoxolone methyl were significantly less likely to experience the composite renal endpoint (hazards ratio 0.48 [95% CI 0.36-0.64]; p < 0.0001). CONCLUSIONS:Bardoxolone methyl preserves kidney function and may delay the onset of ESRD in patients with T2D and stage 4 CKD.
RCT Entities:
BACKGROUND: Increases in measured inulin clearance, measured creatinine clearance, and estimated glomerular filtration rate (eGFR) have been observed with bardoxolone methyl in 7 studies enrolling approximately 2,600 patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The largest of these studies was Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), a multinational, randomized, double-blind, placebo-controlled phase 3 trial which enrolled patients with T2D and CKD stage 4. The BEACON trial was terminated after preliminary analyses showed that patients randomized to bardoxolone methyl experienced significantly higher rates of heart failure events. We performed post-hoc analyses to characterize changes in kidney function induced by bardoxolone methyl. METHODS:Patients in -BEACON (n = 2,185) were randomized 1: 1 to receive once-daily bardoxolone methyl (20 mg) or placebo. We compared the effects of bardoxolone methyl and placebo on a post-hoc composite renal endpoint consisting of ≥30% decline from baseline in eGFR, eGFR <15 mL/min/1.73 m2, and end-stage renal disease (ESRD) events (provision of dialysis or kidney transplantation). RESULTS: Consistent with prior studies, patients randomized to bardoxolone methyl experienced mean increases in eGFR that were sustained through study week 48. Moreover, increases in eGFR from baseline were sustained 4 weeks after cessation of treatment. Patients randomized to bardoxolone methyl were significantly less likely to experience the composite renal endpoint (hazards ratio 0.48 [95% CI 0.36-0.64]; p < 0.0001). CONCLUSIONS:Bardoxolone methyl preserves kidney function and may delay the onset of ESRD in patients with T2D and stage 4 CKD.
Authors: Qing Qing Wu; Yanxia Wang; Martin Senitko; Colin Meyer; W Christian Wigley; Deborah A Ferguson; Eric Grossman; Jianlin Chen; Xin J Zhou; John Hartono; Pamela Winterberg; Bo Chen; Anapam Agarwal; Christopher Y Lu Journal: Am J Physiol Renal Physiol Date: 2011-02-02
Authors: Dick de Zeeuw; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Heidi Christ-Schmidt; Angie Goldsberry; Mark Houser; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; Janet Wittes; Danielle Wrolstad; Glenn M Chertow Journal: N Engl J Med Date: 2013-11-09 Impact factor: 91.245
Authors: Lesley A Inker; Hiddo J Lambers Heerspink; Hasi Mondal; Christopher H Schmid; Hocine Tighiouart; Farzad Noubary; Josef Coresh; Tom Greene; Andrew S Levey Journal: Am J Kidney Dis Date: 2014-10-16 Impact factor: 8.860
Authors: Pablo E Pergola; Philip Raskin; Robert D Toto; Colin J Meyer; J Warren Huff; Eric B Grossman; Melissa Krauth; Stacey Ruiz; Paul Audhya; Heidi Christ-Schmidt; Janet Wittes; David G Warnock Journal: N Engl J Med Date: 2011-06-24 Impact factor: 91.245
Authors: Pablo E Pergola; Melissa Krauth; J Warren Huff; Deborah A Ferguson; Stacey Ruiz; Colin J Meyer; David G Warnock Journal: Am J Nephrol Date: 2011-04-21 Impact factor: 3.754
Authors: Lauren M Aleksunes; Michael J Goedken; Cheryl E Rockwell; Juergen Thomale; Jose E Manautou; Curtis D Klaassen Journal: J Pharmacol Exp Ther Date: 2010-07-06 Impact factor: 4.030
Authors: Dick de Zeeuw; Tadao Akizawa; Rajiv Agarwal; Paul Audhya; George L Bakris; Melanie Chin; Melissa Krauth; Hiddo J Lambers Heerspink; Colin J Meyer; John J McMurray; Hans-Henrik Parving; Pablo E Pergola; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; David G Warnock; Janet Wittes; Glenn M Chertow Journal: Am J Nephrol Date: 2013-02-28 Impact factor: 3.754
Authors: Melanie P Chin; Danielle Wrolstad; George L Bakris; Glenn M Chertow; Dick de Zeeuw; Angie Goldsberry; Peter G Linde; Peter A McCullough; John J McMurray; Janet Wittes; Colin J Meyer Journal: J Card Fail Date: 2014-10-13 Impact factor: 5.712
Authors: Johannes F E Mann; Damian Green; Kenneth Jamerson; Luis M Ruilope; Susan J Kuranoff; Thomas Littke; Giancarlo Viberti Journal: J Am Soc Nephrol Date: 2010-02-18 Impact factor: 10.121
Authors: Mohammad A Aminzadeh; Scott A Reisman; Nosratola D Vaziri; Mahyar Khazaeli; Jun Yuan; Colin J Meyer Journal: Xenobiotica Date: 2013-11-06 Impact factor: 1.908
Authors: Dana V Rizk; Arnold L Silva; Pablo E Pergola; Robert Toto; David G Warnock; Melanie P Chin; Angie Goldsberry; Megan O'Grady; Colin J Meyer; Peter A McCullough Journal: Cardiorenal Med Date: 2019-06-06 Impact factor: 2.041
Authors: Julia M D Grandjean; Lars Plate; Richard I Morimoto; Michael J Bollong; Evan T Powers; R Luke Wiseman Journal: ACS Chem Biol Date: 2019-03-13 Impact factor: 5.100